Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -46.23% | -9.50% | 78.79% | 51.27% | 104.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.23% | -9.50% | 78.79% | 51.27% | 104.76% |
| Cost of Revenue | -14.88% | -25.54% | -26.12% | -27.69% | -3.38% |
| Gross Profit | 9.49% | 28.44% | 41.68% | 34.87% | 11.43% |
| SG&A Expenses | 39.03% | 20.12% | -3.15% | 3.59% | -40.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.08% | -15.90% | -18.48% | -18.60% | -14.90% |
| Operating Income | -2.51% | 16.78% | 27.66% | 23.00% | 20.89% |
| Income Before Tax | -5.31% | 15.83% | 25.69% | 25.34% | 31.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.31% | 15.83% | 25.69% | 25.34% | 31.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.31% | 15.83% | 25.69% | 25.34% | 31.11% |
| EBIT | -2.51% | 16.78% | 27.66% | 23.00% | 20.89% |
| EBITDA | -2.94% | 16.89% | 28.05% | 23.28% | 21.20% |
| EPS Basic | 18.15% | 26.48% | 34.71% | 31.56% | 35.60% |
| Normalized Basic EPS | 18.98% | 25.80% | 35.58% | 27.61% | 24.26% |
| EPS Diluted | 18.15% | 26.48% | 34.71% | 31.56% | 35.60% |
| Normalized Diluted EPS | 18.98% | 25.80% | 35.58% | 27.61% | 24.26% |
| Average Basic Shares Outstanding | 28.68% | 14.48% | 13.81% | 9.09% | 6.97% |
| Average Diluted Shares Outstanding | 28.68% | 14.48% | 13.81% | 9.09% | 6.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |